
This study investigates the clinical outcomes of first-line systemic therapies in renal cell carcinoma (RCC) patients after adjuvant immunotherapy. The study reveals that certain patients, particularly those with favorable-risk disease, benefit from VEGF-targeted therapies. Adverse events were common but manageable. The findings suggest a need for advanced diagnostic tools to optimize treatment strategies in recurrent RCC following adjuvant immunotherapy.
Like
Save
Share